EyePoint, Inc. (EYPT) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Okay, and our next question comes from the line of Tess Romero with JP Morgan. Our next question comes from the line of Tess Romero with JP Morgan. Good morning. My name is Brittany, and I'll be your conference operator today. At this time, I would like to welcome everyone to the iPoint first quarter 2026 financial results and recent corporate development conference call. There will be a question and answer session to follow the completion of prepared remarks. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to George Elston, Executive Vice President and Chief Financial Officer of iPoint. Thank you, and thank you all for joining us on today's conference call to discuss iPoint's first quarter 2026 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer of iPoint. Jay will begin with a review of recent corporate updates and discuss our ongoing clinical programs for DuraView and WED-AMD and DME. I will close with commentary on the first quarter 2026 financial results. We will then open the call for your questions, where we will be joined by Dr. Romero-Ribero, our Chief Medical Officer, and Mike Campbell, our Chief Commercial Officer. Earlier this morning, we issued a press release detailing our financial results and recent corporate developments. A copy of the release can be found in the Investor Relations tab on the company website, www.ipoint.bio. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, ...